By Fineline Cube 
UCB (EBR: UCB) announced National Medical Products Administration (NMPA) approval for Bimzelx (bimekizumab) in two new indications: moderate-to-severe plaque psoriasis (systemic therapy/phototherapy candidates) and moderate-to-severe hidradenitis suppurativa (HS/acne inversa) (inadequate response to conventional therapy). The IL-17A and IL-17F dual-target antibody becomes the first and only approved IL-17A/F biologic in China, expanding from rheumatology/immunology into dermatology for 7+ million psoriasis patients and the rare disease HS population.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Two new indications for existing biologic |
| Product | Bimzelx (bimekizumab) – IL-17A/F dual-target antibody |
| Developer | UCB (EBR: UCB) – Belgium-based biopharma |
| New Indications | 1. Moderate-to-severe plaque psoriasis (systemic/phototherapy candidates) 2. Moderate-to-severe hidradenitis suppurativa (post-conventional therapy failure) |
| Global Positioning | First and only approved IL-17A/F dual-target biologic in China |
Disease Context & Market Opportunity
| Indication | China Burden | Clinical Characteristics | Bimzelx Value Proposition |
|---|---|---|---|
| Plaque Psoriasis (PsO) | >7 million patients; most common psoriasis subtype | Chronic inflammatory skin disease; significant quality-of-life impact | IL-17A/F dual blockade – enhanced efficacy vs. IL-17A monotherapy (Cosentyx) or IL-23 inhibitors |
| Hidradenitis Suppurativa (HS) | Rare disease (China 2nd batch rare disease list) | Chronic, recurrent, painful nodules/abscesses/fistulas (axilla, groin, buttocks); severe pain; disabling flares | First-line biologic option for inadequate conventional therapy responders; addresses unmet need in rare inflammatory skin disease |
Strategic Context & Competitive Position
| Factor | Implication |
|---|---|
| IL-17A/F Dual-Target Differentiation | Simultaneous inhibition of IL-17A (pro-inflammatory) + IL-17F (tissue damage) provides superior skin clearance and sustained response vs. monospecific competitors |
| China Dermatology Expansion | UCB’s first dermatology indication approvals in China – leverages existing rheumatology infrastructure for cross-specialty promotion |
| Competitive Landscape | Cosentyx (Novartis, IL-17A) and Tremfya (J&J, IL-23) dominate psoriasis; Bimzelx’s dual-target mechanism + rapid onset differentiates in biologic-naïve and switch populations |
| HS Market Development | Rare disease designation supports NRDL negotiation advantages; limited approved therapies (adalimumab biosimilars) creates first-mover opportunity |
| Global Franchise | Bimzelx already approved psoriatic arthritis, axial spondyloarthritis in China; dermatology expansion completes IL-17A/F immunology ecosystem |
- Commercial Timeline: Launch preparation Q2 2026; hospital dermatology and rheumatology joint detailing; NRDL inclusion 2027 for psoriasis (HS likely commercial insurance/patient assistance given rarity)
- Revenue Potential: China peak sales RMB 800 million–1.2 billion across immunology-dermatology indications; HS rare disease pricing supports premium positioning
Forward‑Looking Statements
This brief contains forward‑looking statements regarding commercial launch execution, physician adoption across dermatology-rheumatology, and reimbursement negotiations for Bimzelx in China. Actual results may differ due to competitive dynamics with IL-23 inhibitors, biosimilar pressure on IL-17A monotherapies, and rare disease policy implementation variability.-Fineline Info & Tech